PreludeDx™ Presents New Data at the 40th Annual Miami Breast Cancer Conference Identifying Which Patients with DCIS May Be Undertreated Based on Clinicopathologic Factors Alone

Using 10-yr Outcomes Data, DCISionRT Reclassified Nearly 70% of CP Model Low-Risk Patients to Elevated Risk LAGUNA HILLS, Calif., March 2, 2023 /PRNewswire/ — Prelude Corporation (PreludeDx™), a leader in molecular diagnostics and precision medicine for early-stage breast cancer, today…

Leave a Reply

Your email address will not be published. Required fields are marked *